IRadimed Corporation (IRMD) Stock Grade

About IRadimed Corporation's fundamentals

IRadimed Corporation generates strong profitability with a net margin of 26.8% and a return on equity of 23.8%, indicating efficient operations and effective capital deployment. The company is experiencing solid revenue growth of 14.4% year-over-year, though this expansion is reflected in a notably elevated P/E ratio of 55.1, suggesting investors are pricing in expectations for continued growth. With a market capitalization of $1.2 billion and a modest dividend yield of 1.3%, the company prioritizes reinvestment over shareholder payouts.